In addition, through drug sensitivity prediction, we screened drugs with better sensitivity for patients in the high-risk scoring group from numerous clinical and preclinical chemotherapy and targeted drugs, such as the current clinical drugs lapatinib (a dual tyrosine kinase inhibitor that inhibits both EGFR and HER2), docetaxel, and paclitaxel, as well as candidate anti-cancer drugs BI-2536 (a known potent human polo-like kinase 1 inhibitor) and sepantronium bromide (a small molecule survivin inhibitor), and ULK1 (a ULK1 inhibitor). Here, PLK1 is linked to cancer.